The prevalence of HBeAg was studied in Korean patients with chronic active hepatitis, cirrhosis and primary hepatocellular carcinoma. There is an independent association of HBeAg prevalence with age and diagnosis. These findings are discussed in terms of a developmental model for primary hepatocellular carcinoma which could explain the lower frequency of HBeAg in the cancer cases.
This study was conducted to investigate the modulatory effects of recombinant human tumor necrosis factor (rH‐TNF) and recombinant human interferon (rH‐IFN)‐α, ‐β and ‐γ, either alone or in combination, on the cytotoxicity of cisplatin, using MTT assay, against MKN‐45 (human stomach adenocarcinoma). MKN‐45 was resistant to rH‐TNF even at doses up to 103 U/ml. rH‐IFN‐γ inhibited the survival of MKN‐45 dose‐dependently, while rH‐IFN‐α and ‐β did not inhibit the survival of MKN‐45 even at the highest concentrations tested (104 U/ml). Combination of rH‐TNF with rH‐IFN‐α, ‐β or ‐γ did not significantly inhibit the survival of MKN‐45, except for a combination of 10 U/ral of rH‐TNF and 103 U/ml of rH‐IFN‐γ (P<0.05). Cisplatin inhibited the survival of MKN‐45 dose‐dependently. By the simultaneous combination of cisplatin with rH‐TNF and/or rH‐IFN‐α, ‐β or γ, cytotoxicity of cisplatin was enhanced and the combination effects were additive. The effects of rH‐TNF and rH‐IFN‐α, β and ‐γ on the modification of cytotoxicity of cisplatin were evaluated in terms of modification index (MI), demonstrating that rH‐TNF, rH‐IFN‐α, ‐β and ‐γ all augmented the cytotoxicity of cisplatin: MI values at 103 U/ml of rH‐IFN‐α, ‐β and ‐γ were 1.4, 1.4 and 2.3, respectively; those at the same concentrations of rH‐IFN‐α, ‐β and ‐γ in the presence of 10 U/ml of rH‐TNF were 3.6, 2.5 and 5.1, respectively. These results demonstrating that the cytotoxicity of cisplatin was enhanced by rH‐TNF and/or rH‐IFN‐α, ‐β or ‐γ suggest that cancer may be more effectively treated with the combination of cisplatin with these biological response modifiers than with cisplatin alone.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.